Get the Stockscreener App
1.99
0.00%
0.00
After Hours:
2.05
0.06
+3.02%
Milestone Pharmaceuticals Inc stock is traded at $1.99, with a volume of 1.64M.
It is up +0.00% in the last 24 hours and up +1.53% over the past month.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
See More
Previous Close:
$1.99
Open:
$2.03
24h Volume:
1.64M
Relative Volume:
1.03
Market Cap:
$169.14M
Revenue:
-
Net Income/Loss:
$-59.69M
P/E Ratio:
-1.4317
EPS:
-1.39
Net Cash Flow:
$-46.54M
1W Performance:
-6.13%
1M Performance:
+1.53%
6M Performance:
+158.01%
1Y Performance:
+37.24%
1-Day Range:
$1.96
$2.06
1-Week Range:
$1.96
$2.14
52-Week Range:
$0.6254
$2.75
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
Name
Milestone Pharmaceuticals Inc
Sector
Industry
Phone
(514) 336-0444
Address
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Compare MIST with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
1.99 | 169.14M | 0 | -59.69M | -46.54M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-11-25 | Initiated | Wells Fargo | Overweight |
| Jun-05-25 | Resumed | H.C. Wainwright | Buy |
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Jun-20-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-22-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-05-21 | Initiated | H.C. Wainwright | Buy |
| Jul-29-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-24-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-25-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-24-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-24-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-04-19 | Initiated | Oppenheimer | Outperform |
| Jun-03-19 | Initiated | Cowen | Outperform |
| Jun-03-19 | Initiated | Jefferies | Buy |
| Jun-03-19 | Initiated | Piper Jaffray | Overweight |
View All
Milestone Pharmaceuticals Inc Stock (MIST) Latest News
Milestone Pharmaceuticals Inc.’s volatility index tracking explainedWeekly Stock Analysis & Safe Capital Investment Plans - newser.com
Will Milestone Pharmaceuticals Inc. stock remain a Wall Street favorite2025 Earnings Impact & Reliable Price Action Trade Plans - newser.com
Milestone Pharmaceuticals Inc Stock Analysis and ForecastTrading Volume Trends & Big Data Market Reports - earlytimes.in
Is Milestone Pharmaceuticals Inc. forming a bottoming baseWeekly Volume Report & Real-Time Volume Trigger Notifications - newser.com
Published on: 2025-10-10 05:09:19 - newser.com
Brokerages Set Milestone Pharmaceuticals Inc. (NASDAQ:MIST) PT at $4.50 - Defense World
Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025 - The Manila Times
Milestone Pharmaceuticals to Present Etripamil Data at AHA Scientific Sessions 2025 - Quiver Quantitative
Published on: 2025-10-09 06:06:14 - newser.com
Is December The Breakthrough Moment For MIST? - RTTNews
Will Milestone Pharmaceuticals Inc. stock reach Wall Street targetsQuarterly Trade Summary & Intraday High Probability Alerts - newser.com
Visualizing Milestone Pharmaceuticals Inc. stock with heatmaps2025 Technical Patterns & Fast Entry Momentum Alerts - newser.com
Is Milestone Pharmaceuticals Inc. stock a safe investment in uncertain marketsJuly 2025 Reactions & Technical Entry and Exit Alerts - newser.com
Milestone Pharmaceuticals: Playing The Long Ball In Cardiovascular Treatment (NASDAQ:MIST) - Seeking Alpha
How hedge fund analytics apply to Milestone Pharmaceuticals Inc. stockTrade Risk Summary & Community Shared Stock Ideas - newser.com
Chart based analysis of Milestone Pharmaceuticals Inc. trendsGDP Growth & Weekly Market Pulse Updates - newser.com
Milestone Pharmaceuticals Inc. stock daily chart insightsJuly 2025 Summary & Stock Timing and Entry Methods - newser.com
Is Milestone Pharmaceuticals Inc. forming a reversal patternIPO Watch & Risk Managed Investment Signals - newser.com
Candlestick signals on Milestone Pharmaceuticals Inc. stock todaySwing Trade & AI Based Buy/Sell Signal Reports - newser.com
How Milestone Pharmaceuticals Inc. stock trades during market volatility - newser.com
Will Milestone Pharmaceuticals Inc. stock reach all time highs in 2025Market Rally & Scalable Portfolio Growth Methods - newser.com
What analysts say about Milestone Pharmaceuticals Inc stockMarket Insider Reports & Build Your Portfolio With Our Free Stock Scanner - earlytimes.in
Published on: 2025-09-29 11:35:53 - newser.com
Real time scanner hits for Milestone Pharmaceuticals Inc. explainedBear Alert & Daily Price Action Insights - newser.com
Milestone Pharmaceuticals Inc Stock (MIST) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):